8-K: FMC Corp. Reports Q2 2026 Results, Updates Full-Year Outlook

FMC Corporation announced second quarter 2026 financial results, with Adjusted EBITDA exceeding guidance, while also revising its full-year outlook to reflect a more challenging macro environment.

Summary

• FMC Corporation reported second quarter 2026 revenue of $867 million, a 17% decrease compared to the second quarter of 2025. Excluding India, revenue was $841 million, down 20%.
• The company reported a consolidated GAAP net loss of $187 million, or $1.49 per diluted share, a significant decline from the prior year.
• Adjusted EBITDA for the quarter was $153 million, down 26% year-over-year, though it exceeded the high end of the company's guidance range.
• GAAP cash from operations was $363 million, an increase of $297 million, boosted by a $200 million upfront payment for a rimisoxafen licensing agreement.
• The company has updated its full-year 2026 outlook, lowering revenue guidance to $3.50 billion $3.70 billion (a 7% decline at the midpoint) and Adjusted EBITDA to $620 million $680 million (a 23% decline at the midpoint).
• Full-year Adjusted EPS is now projected to be between $1.19 and $1.49, a 55% decrease at the midpoint.
• Free cash flow guidance for the full year has been increased to a range of $75 million to $225 million, now including the $200 million rimisoxafen licensing payment.
• FMC has concluded its strategic options review, focusing on debt reduction, core portfolio competitiveness, post-patent transition for Rynaxypyr, and accelerating new active ingredient growth.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative sentiment due to significant year-over-year declines in revenue and profitability, coupled with a lowered full-year outlook, despite some positive cash flow generation and exceeding EBITDA guidance for the quarter.

Positives

• Adjusted EBITDA of $153 million for Q2 2026 was above the high end of the guidance range.
• GAAP cash from operations increased significantly by $297 million to $363 million in Q2 2026, aided by a $200 million licensing payment.
• Free cash flow for Q2 2026 was $357 million, an improvement of $318 million year-over-year.
• The company expects a return to year-over-year revenue growth in the fourth quarter of 2026.
• The growth portfolio, excluding Plant Health, grew mid-single digits, driven by new active ingredients and Cyazypyr active.
• FMC is on track to generate approximately $1 billion in proceeds for debt reduction through various strategic actions.

Negatives

• Q2 2026 revenue of $867 million decreased by 17% compared to Q2 2025.
• Consolidated GAAP net loss was $187 million in Q2 2026, a decline of $253 million from Q2 2025.
• Adjusted earnings per diluted share decreased by 62% to $0.26 in Q2 2026 compared to Q2 2025.
• Full-year revenue outlook lowered to $3.50 billion $3.70 billion, a 7% decline at the midpoint.
• Full-year Adjusted EBITDA outlook lowered to $620 million $680 million, a 23% decline at the midpoint.
• Full-year Adjusted EPS outlook lowered to $1.19 $1.49, a 55% decline at the midpoint.
• Third quarter 2026 Adjusted EBITDA is forecasted to decrease by 45% year-over-year.
• Third quarter 2026 Adjusted EPS is forecasted to decline by 90% year-over-year.

Risks

• Challenging macro environment impacting customer purchasing patterns and market conditions.
• Lower demand for core legacy products, particularly in North America, due to strained grower margins.
• Reduced diamide partner orders impacting volume.
• Pressure on pricing for core legacy products.
• Foreign currency headwinds are expected for the full year.
• The sale of the India commercial business, Newark property sale, and Tessenderlo Group investment are subject to closing conditions, including regulatory approvals.
• Potential for further changes in estimates for environmental liabilities and legal reserves.

Future Outlook

The company has updated its full-year 2026 outlook, projecting revenue between $3.50 billion and $3.70 billion (a 7% decline at the midpoint), Adjusted EBITDA between $620 million and $680 million (a 23% decline at the midpoint), and Adjusted EPS between $1.19 and $1.49 (a 55% decline at the midpoint). Free cash flow is now expected to be between $75 million and $225 million. The company anticipates a return to year-over-year revenue growth in the fourth quarter of 2026.

Management Comments

• "During the quarter, we completed several important actions that strengthened FMC's financial foundation and provide greater flexibility to execute our strategy," said Pierre Brondeau, chairman, chief executive officer and president.
• "With the strategic review now concluded, we have clarity on the path forward and remain focused on improving competitiveness, advancing our technology portfolio and positioning the company for long-term growth."

Industry Context

StockSavvy.ai notes that FMC's updated outlook reflects a challenging macro environment impacting the agricultural sciences sector, characterized by strained grower margins and shifts in demand for crop protection products. The company's focus on operational priorities and new active ingredients aligns with industry trends towards innovation and efficiency.

Comparison to Industry Standards

• No direct comparisons to specific industry benchmarks or competitors were provided in the filing.
• The filing indicates a decline in revenue and profitability, which may be influenced by broader agricultural market conditions affecting companies like Bayer, Syngenta, and Corteva.

Stakeholder Impact

• Shareholders: Potential negative impact due to reduced earnings per share and lowered full-year outlook, offset by strategic actions aimed at debt reduction and long-term growth.
• Creditors: Positive impact from planned debt reduction initiatives.
• Employees: Potential impact from restructuring charges related to Project Foundation, aimed at optimizing cost structure and operations.
• Customers: May experience shifts in product availability or pricing due to market conditions and strategic changes.

Next Steps

• Continue to focus on improving competitiveness.
• Advance the company's technology portfolio.
• Position the company for long-term growth.
• Complete the sale of the India commercial business.
• Complete the sale-leaseback agreement for the Newark, Delaware property.
• Utilize proceeds from strategic actions for debt reduction.

Key Dates

Recommendation

The company is facing significant headwinds with declining revenues and profits, and has lowered its full-year guidance. While the company is taking strategic steps to reduce debt and improve its financial foundation, the near-term outlook remains challenging. The equity investment from Tessenderlo Group provides some stability, but the overall performance suggests a cautious 'hold' rating until a clear recovery path is demonstrated.

Keywords

Agricultural Sciences, Crop Protection, Insecticides, Herbicides, Fungicides, Active Ingredients, Rynaxypyr, Cyazypyr